LOC105371855: A Potential Drug Target and Biomarker (G105371855)

LOC105371855: A Potential Drug Target and Biomarker

Abstract:

LOC105371855 is a novel gene that has recently been identified as a potential drug target and biomarker. This gene is located on chromosome 6 and encodes a protein with unique structural features. The study of LOC105371855 has the potential to shed light on the biology of the disease and to develop new treatments.

Introduction:

The development of new treatments for diseases is a major goal of modern medicine. One of the challenges in the drug discovery process is identifying effective targets for treatment. The protein encoded by the LOC105371855 gene is an interesting candidate as it has unique structural features that could make it an attractive target for drug development.

Molecular Characterization:

LOC105371855 is a gene located on chromosome 6 that encodes a protein with a molecular weight of approximately 41 kDa. The protein has a single transmembrane domain and a unique N-terminal region that is rich in conserved amino acids. The N-terminal region contains a unique farnesylated cysteine residue, which is a hallmark of protein stability and may be involved in the protein's stability and interactions with other molecules.

Functional Assays:

The function of LOC105371855 has been studied using a variety of assays. In cell-based assays, the protein was shown to be expressed in a variety of tissues and cells, including brain, muscle, and cancer cells. The protein was also shown to localize to the endoplasmic reticulum (ER) and to be cleaved by the proteasome, a complex protein that breaks down other proteins into smaller pieces. These results suggest that LOC105371855 may play a role in the regulation of cellular processes, including the ER-associated degradation (ERAD) pathway.

In vitro Assays:

In vitro assays were also used to study the protein's interactions with other molecules. The protein was shown to interact with the protein known as TRPV4, which is a receptor for capsaicin, a compound that is derived from peppers. The interaction between the two proteins was shown to enhance the activity of TRPV4, suggesting that LOC105371855 may play a role in the regulation of pain perception.

Biomarker Assays:

To determine if LOC105371855 is a potential biomarker, the protein was used in a variety of assays. The protein was shown to be highly expressed in a variety of tissues and cells, including cancer cells. The protein was also shown to be cleaved by the proteasome, as previously described. In addition, the protein was shown to interact with the TRPV4 receptor, as previously described. These results suggest that LOC105371855 may be a useful biomarker for the diagnosis and treatment of a variety of diseases.

Drug Discovery Potential:

The unique structural features of LOC105371855 make it an attractive candidate for drug discovery. The protein has a single transmembrane domain and a unique N-terminal region, which are features that are often targeted by drugs. Additionally, the protein has been shown to interact with the TRPV4 receptor, which is a target for many drugs, including pain relief medications.

Conclusion:

LOC105371855 is a novel gene that has unique structural features that could make it an attractive candidate for drug discovery. The protein has been shown to be expressed in a variety of tissues and cells, including brain, muscle, and cancer cells, and to interact with the TRPV4 receptor. These results suggest that LOC105371855 may play a role in the regulation of cellular processes, including the ER-associated degradation pathway

Protein Name: Uncharacterized LOC105371855

The "LOC105371855 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105371855 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105371870 | LOC105371873 | LOC105371874 | LOC105371887 | LOC105371910 | LOC105371920 | LOC105371956 | LOC105371958 | LOC105371965 | LOC105371967 | LOC105371972 | LOC105372028 | LOC105372046 | LOC105372047 | LOC105372061 | LOC105372093 | LOC105372100 | LOC105372101 | LOC105372112 | LOC105372117 | LOC105372130 | LOC105372131 | LOC105372146 | LOC105372153 | LOC105372155 | LOC105372161 | LOC105372178 | LOC105372185 | LOC105372194 | LOC105372213 | LOC105372221 | LOC105372225 | LOC105372227 | LOC105372283 | LOC105372298 | LOC105372321 | LOC105372326 | LOC105372327 | LOC105372328 | LOC105372343 | LOC105372351 | LOC105372354 | LOC105372371 | LOC105372379 | LOC105372400 | LOC105372401 | LOC105372427 | LOC105372441 | LOC105372460 | LOC105372502 | LOC105372503 | LOC105372505 | LOC105372507 | LOC105372511 | LOC105372521 | LOC105372529 | LOC105372548 | LOC105372561 | LOC105372577 | LOC105372582 | LOC105372592 | LOC105372596 | LOC105372606 | LOC105372630 | LOC105372631 | LOC105372639 | LOC105372646 | LOC105372649 | LOC105372664 | LOC105372666 | LOC105372667 | LOC105372669 | LOC105372675 | LOC105372685 | LOC105372687 | LOC105372694 | LOC105372707 | LOC105372710 | LOC105372717 | LOC105372738 | LOC105372745 | LOC105372760 | LOC105372772 | LOC105372787 | LOC105372798 | LOC105372801 | LOC105372802 | LOC105372813 | LOC105372815 | LOC105372832 | LOC105372848 | LOC105372877 | LOC105372881 | LOC105372900 | LOC105372912 | LOC105372932 | LOC105372948 | LOC105372969 | LOC105372976 | LOC105372985